Anti-CD3 Antibody - 2018 Pipeline Insight Report - ResearchAndMarkets.com

DUBLIN--()--The "Anti-CD3 Antibody -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD3 Antibody development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Scope

  • Provides a snapshot of the therapeutics pipeline activity for Anti-CD3 Antibody
  • Features the Anti-CD3 Antibody pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Anti-CD3 Antibody with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Anti-CD3 Antibody
Companies Featured
  • Affimed Therapeutics
  • MacroGenics
  • Roche
  • Tolerance Therapeutics
  • Emergent BioSolutions
  • Genentech
  • MacroGenics
  • NovImmune S.A.
  • Micromet Inc.

Key Topics Covered

1. Report Introduction

2. Anti-CD3 Antibody - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Anti-CD3 Antibody

4. Comparative Analysis

5. Anti-CD3 Antibody Pipeline Products in Clinical Stages

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Anti-CD3 Antibody Pipeline Products in Non-clinical Stages

6.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

8.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6kd6cw/anticd3_antibody?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs